Sanofi
Nucleic acids encoding antibodies to Kallidin and des-Arg.sub.10-Kallidin and host cells comprising the same
Last updated:
Abstract:
The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg.sub.9-Bradykinin and des-Arg.sub.10-Kallidin-like peptide.
Status:
Grant
Type:
Utility
Filling date:
18 Dec 2017
Issue date:
5 Nov 2019